Study of ALT001 for people with ALS
Treatments studied
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This study tests an investigational drug called ALT001 in people with amyotrophic lateral sclerosis (ALS), a disease that affects nerve cells controlling muscles. The goal is to see if ALT001 can help slow the progression of the disease. Participants will receive the drug and be monitored for safety and effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a diagnosis of definite or probable ALS (either inherited or not).
- Your breathing capacity (measured by a test called FVC) is at least 50% of what is expected for your age and size.
- Your ALS symptoms, measured by a standard scale, are within a certain range (score between 30 and 40).
- If you take riluzole or edaravone for ALS, you have been on a stable dose for at least 30 days before starting the study.
- You are not currently using a breathing machine (like a ventilator or BiPAP) on a regular basis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug (FHND1002) for people with ALS to see if it can slow down the disease. It's for people with ALS who are in the early to moderate stages, have good breathing, and have been recently diagnosed.
This study tests an investigational drug called NB-4746 for people with ALS. The goal is to see if it can slow the progression of the disease. It is for people diagnosed within the last couple of years who are still able to eat and breathe on their own.
This study tests a new gene therapy called VGN-R13 for people with ALS. It aims to see if the treatment is safe and tolerable, and if it can slow down the disease. You may be able to join if your ALS symptoms started recently and your lung function is still fairly good.
This trial tests an experimental drug called ALN-SOD for people with ALS caused by a specific genetic mutation in the SOD1 gene. The goal is to see if it is safe and can help slow the disease.
This trial tests a new medicine, CB03-154, to see if it can help people with ALS. Researchers are comparing different doses to find the safest and most effective one.
This early-stage trial tests a new biologic treatment called ALT001 in people with multiple system atrophy-cerebellar type (MSA-C), a rare neurological condition affecting balance and coordination. The study focuses on whether ALT001 is safe and whether it shows early signs of helping slow disease progression.
Hear when a new Amyotrophic Lateral Sclerosis (ALS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.